HER2-Positive Solid Tumors
8
2
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
A Phase 1/1b Study of IAM1363 in HER2 Cancers
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
A Study of VRN101099 in Patients With HER2-Positive Solid Tumors
A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors
JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors
A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients